Baylor University Medical Center

Running trials

• Not yet recruiting

  An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

  NCT07923526· Phase 2/3· United Therapeutics· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Closed-Loop Vagus Nerve Stimulation (CLV) for Recovery of Gait After Spinal Cord Injury (SCI)

  NCT07689227· The University of Texas at Dallas· Source

• Not yet recruiting

  A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment

  NCT07926321· Phase 2· Boehringer Ingelheim· Source

• Not yet recruiting

  Smartphone-enabled Hybrid Identification of Early CoLorectal Disease Using Blood-Based Cancer Testing Across TeXas

  NCT07398456· Baylor Research Institute· Source

• Not yet recruiting

  Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)

  NCT07923591· Phase 2· United Therapeutics· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

  NCT06732388· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

  NCT07115940· Amrou Sarraj· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  NCT07280013· Phase 1· C4 Therapeutics, Inc.· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT07222761· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  A Polypill for Acute Coronary Syndrome

  NCT07032389· Phase 2· University of Texas Southwestern Medical Center· Source

• Recruiting

  OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

  NCT06939751· Northwestern University· Source

• Recruiting

  A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  NCT07196722· Phase 2/3· Janssen Research & Development, LLC· Source

• Recruiting

  Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  NCT06911632· Tempus AI· Source

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  NCT06852222· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Combined Role of Gastric Peroral Endoscopic Myotomy and Gastric Electrical Stimulator

  NCT07526935· Baylor Research Institute· Source

• Active, not recruiting

  Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

  NCT06868290· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

  NCT06778863· Phase 1· Clasp Therapeutics, Inc.· Source

• Recruiting

  DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  NCT06388421· United Therapeutics· Source

• Recruiting

  Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  NCT06736574· Phase 3· Cytokinetics· Source

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Recruiting

  Tirzepatide Weight Loss for MRD+ Early Breast Cancer

  NCT06517212· Phase 2· Baylor Research Institute· Source

• Active, not recruiting

  Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  NCT06310031· BrioHealth Solutions, Inc.· Source

• Enrolling by invitation

  Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma

  NCT06609239· Phase 2· Sanofi· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Neratinib in Combination With Ruxolitinib in Patients With mTNBC

  NCT06008275· Early phase 1· Baylor Research Institute· Source

• Enrolling by invitation

  Vagus Nerve Stimulation (VNS) in Spinal Cord Injury (SCI) Adaptive Follow-On Study

  NCT06351111· The University of Texas at Dallas· Source

• Recruiting

  Study of XB010 in Subjects With Solid Tumors

  NCT06545331· Phase 1· Exelixis· Source

• Active, not recruiting

  A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06425991· Phase 1· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

  NCT06226571· Phase 1· Syndax Pharmaceuticals· Source

• Recruiting

  A Registry for People With Lung Cancer

  NCT06424327· Memorial Sloan Kettering Cancer Center· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Avalyn Pharma Inc.· Source

• Recruiting

  MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  NCT06152575· Phase 3· Pfizer· Source

• Recruiting

  Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05571059· Phase 2· Cumberland Pharmaceuticals· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· United Therapeutics· Source

• Recruiting

  Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  NCT05826535· Phase 1/2· Lyell Immunopharma, Inc.· Source

• Recruiting

  Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

  NCT05753748· University of Colorado, Denver· Source

• Active, not recruiting

  A Study of Daratumumab

  NCT05438043· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

  NCT05768932· Phase 1· SillaJen, Inc.· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· United Therapeutics· Source

• Active, not recruiting

  A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT05242471· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma

  NCT04980222· Phase 2· Hoffmann-La Roche· Source

• Enrolling by invitation

  Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite Studies

  NCT05041309· Phase 2· Kite, A Gilead Company· Source

Showing 50 of 79.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple myeloma6 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• COPD4 recruiting
• Heart failure4 recruiting
• High blood pressure4 recruiting
• Pulmonary arterial hypertension4 recruiting
• Triple-negative breast cancer4 recruiting
• Gastric and oesophageal cancer3 recruiting
• Lung cancer3 recruiting
• Acute myeloid leukaemia2 recruiting
• Barrett's oesophagus2 recruiting
• Childhood cancers2 recruiting
• Colorectal cancer2 recruiting
• Crohn's disease2 recruiting
• Spinal cord injury2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Asthma1 recruiting
• Bladder cancer1 recruiting
• Bronchiectasis1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Follicular lymphoma1 recruiting
• Head and neck cancer1 recruiting
• Hepatitis C1 recruiting
• Liver and biliary tract cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Obesity1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Closed trials

• Recruiting

  A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  NCT07623161· Phase 3· Takeda· Source

• Completed

  Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

  NCT06102005· Phase 2· Sanofi· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Terminated

  Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA

  NCT05667662· Phase 2· Pulmatrix Inc.· Source

• Completed

  DORAYA-HF Early Feasibility Study

  NCT05206422· Revamp Medical Inc.· Source

• Terminated

  Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

  NCT05079230· Phase 3· Gilead Sciences· Source

• Completed

  International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

  NCT05387811· Azienda Ospedaliera di Padova· Source

• Terminated

  A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma

  NCT05121103· Phase 1· Epizyme, Inc.· Source

• Terminated

  Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

  NCT05267106· Phase 2· Incyte Corporation· Source

• Completed

  A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

  NCT04945460· Phase 2· Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA· Source

• Completed

  Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca

  NCT04921904· Phase 1/2· Baylor Research Institute· Source

• Completed

  A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)

  NCT04834778· Phase 1· HiberCell, Inc.· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface

  NCT04752215· Phase 1· Boehringer Ingelheim· Source

• Recruiting

  A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  NCT04830137· Phase 1· Nurix Therapeutics, Inc.· Source

• Completed

  MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

  NCT04649359· Phase 2· Pfizer· Source

• Completed

  A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

  NCT03776071· Phase 3· Denovo Biopharma LLC· Source

• Completed

  Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  NCT04471844· NovoCure Ltd.· Source

• Completed

  Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

  NCT03657342· Phase 3· Zambon SpA· Source

• Completed

  Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

  NCT03656926· Phase 3· Zambon SpA· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· United Therapeutics· Source

• Completed

  Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen

  NCT03373227· Phase 2· Baylor Research Institute· Source

• Completed

  PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

  NCT03269136· Phase 1· Pfizer· Source

• Recruiting

  Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction

  NCT02901184· Phase 3· Uppsala University· Source

• Completed

  Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities

  NCT03373279· Baylor Research Institute· Source

• Terminated

  Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

  NCT02629692· Phase 1/2· Sun Pharma Advanced Research Company Limited· Source

• Terminated

  Functional Assessment in Liver Transplantation

  NCT03870568· Baylor Research Institute· Source

• Completed

  MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

  NCT01805076· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Terminated

  Quantitative Liver Function Tests Using Cholates

  NCT01907074· Phase 2· Baylor Research Institute· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Metastatic breast cancer13 works · 1 trial
• Barrett's oesophagus4 works · 2 trials
• Fabry disease3 works · 0 trials